



214775

00-000000000

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at . Please contact CVS/Caremark at 1-888-413-2723 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of the medication.

Pati	ient Name: ient ID: ient Group No:	NPI#:	_ Date: _ Patient Date Of Birth: Patient Phone:	9/9/2024 Physician Name: Specialty: Physician Office Telephone:
Phy	sician Office Address:			- Injulation of the proprieties
Dru	g Name (specify drug)			_
Qua	antity:	Frequency:	Streng	jth:
			Expected Length of Therapy: _ ICD Code:	
Cor				
Plea	ase check the appropriat What is the diagnosis?	e answer for each applical	ble question.	
	Hutchinson-Gilford Pr			
	Processing Deficient I (If checked, go to 7)	Progeroid Laminopathy with	Progerin-Like Protein Accumulation	
	Processing Deficient R Accumulation (If chec	Progeroid Laminopathy withous ked, go to 12)	out Progerin-Like Protein	
	Other, please specify.	(If checked, no further ques	stions)	
2.	Has the diagnosis of Hutesting indicating the patgenetic testing results.	tchinson-Gilford Progeria Sy tient has a LMNA mutation?	vndrome been confirmed with genetic ACTION REQUIRED: If Yes, attach	
	Yes (If checked, go to	3)		
	No (If checked, no fur	ther questions)		
	Unknown (If checked,	no further questions)		
	ACTION REQUIRED:	Submit supporting documer	ntation	
3.	What is the patient's age	?		
	Less than 12 months	of age (If checked, no furthe	er questions)	
	Greater than or equal	to 12 months of age (If chec	cked, go to 4)	
4.	•	dy surface area (BSA) in met s squared (If checked, no fur	·	
	Greater than or equal	to 0.39 meters squared (If c	checked, go to 5)	
5.	Is the patient currently re	eceiving treatment with the re	equested medication?	Y 🔲 N 🗀
6.	Has the patient experien	nced a benefit from therapy?		Y N

7. Has the diagnosis of Processing Deficient Progeroid Laminopathy with Progerin-Like Protein Accumulation been confirmed with genetic testing indicating the patient has a heterozygous LMNA mutation? ACTION REQUIRED: If Yes, attach genetic testing results.

•			
	Yes (If checked, go to 8)		
	No (If checked, no further questions)		
	Unknown (If checked, no further questions)		
	ACTION REQUIRED: Submit supporting documentation		
8.	What is the patient's age?		
	Less than 12 months of age (If checked, no further questions)		
	Greater than or equal to 12 months of age (If checked, go to 9)		
9.	What is the patient's body surface area (BSA) in meters squared?		
	Less than 0.39 meters squared (If checked, no further questions)		
	Greater than or equal to 0.39 meters squared (If checked, go to 10)		
10.	Is the patient currently receiving treatment with the requested medication?	Υ	N 🔲
11.	Has the patient experienced a benefit from therapy?	Υ	N 🔲
12.	Has the diagnosis of Processing Deficient Progeroid Laminopathy without Progerin-Like Protein Accumulation been confirmed with genetic testing indicating the patient has a homozygous or compound heterozygous ZMPSTE24 mutation? ACTION REQUIRED: If Yes, attach genetic testing results.		
	Yes (If checked, go to 13)		
	No (If checked, no further questions)		
	Unknown (If checked, no further questions)		
	ACTION REQUIRED: Submit supporting documentation		
13.	What is the patient's age?		
	Less than 12 months of age (If checked, no further questions)		
	Greater than or equal to 12 months of age (If checked, go to 14)		
14.	What is the patient's body surface area (BSA) in meters squared?	_	
	Less than 0.39 meters squared (If checked, no further questions)		
	Greater than or equal to 0.39 meters squared (If checked, go to 15)		
15.	Is the patient currently receiving treatment with the requested medication?	Υ	N 🔲
16.	Has the patient experienced a benefit from therapy?	Υ	N 🔲

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Prescriber (Or Authorized) Signature and Date

Now you can get responses to drug PAs immediately and securely online—without faxes, phone calls, or waiting. How? With electronic prior authorization (ePA)! For more information and to register, go to www.caremark.com/epa.